Differentiating TROP2-Directed Antibody-Drug Conjugates in NSCLC

Faculty examine the expanding role of TROP2-directed antibody-drug conjugates, emphasizing that agents within this class are not interchangeable. The panel reviews differences in outcomes by histology observed across agents, including data suggesting variable benefit in squamous disease, and considers whether histology may reflect underlying biological factors such as internalization. Discussion addresses toxicity considerations common to antibody-drug conjugates, including cytopenias, stomatitis, and interstitial lung disease, and examines a frontline trial combining a TROP2 agent with immunotherapy, including constructive critique of its control arm and PD-L1 population. Faculty also discuss the rationale for potential synergy between antibody-drug conjugates and immunotherapy, and the importance of duration and dose optimization to preserve quality of life.